AI-powered lung cancer detection
Lucem Health Reveal for Lung Cancer uses a proven AI algorithm to analyze your existing EHR data and identify patients who are more likely to present with lung cancer.
Allowing you to treat lung cancer patients earlier, when outcomes are better and total treatment costs are lower.
Deliver more proactive lung cancer care
Only 6.5% of eligible adults undergo recommended lung cancer screening, and part of why 45% of non-small cell lung cancer diagnoses occur at Stage 4, when the 5-year survival rate is only 9%. Reveal for Lung Cancer creates new opportunity for you to target priority patients for screening.
Reveal for Lung Cancer:
Real return from targeted screening
Consider a population of 58,000 adults meeting USPSTF lung cancer screening criteria. The following scenarios compare the first two years of programs with and without Reveal for Lung Cancer, which targets the 10% of patients flagged for higher apparent risk of lung cancer.
Why Reveal for Lung Cancer?
Deliver timely Dx and treatment
Reveal for Lung Cancer flags patient risks 9-12 months prior to when they would otherwise be diagnosed. With earlier identification, about 15% of Stage 4 cases could instead be identified at Stages 0-3.
Improve patient outcomes
Lung cancer has a 65% survival rate when diagnosed at localized stage, compared to 9% survival rate when diagnosed at Stage 4.
Effectively target higher risk patients
In a typical cohort of screening-eligible patients, Reveal is expected to flag nearly 50% of lung cancer cases.
Enhance clinical yield
With Reveal, find a projected 370% more cases of lung cancer compared to opportunistic USPSTF screening of an equal-size patient cohort.
From Partners You Can Trust
Lucem Health partnered with Medial EarlySign to develop the Reveal for Lung Cancer solution.
About Medial EarlySign
Medial EarlySign’s clinical machine learning software solutions help healthcare stakeholders keep patients healthier longer. Healthcare clients derive actionable and personalized clinical insights from massive amounts of health data leading to potential improvements in quality care, outcomes, diagnostic efficiency, and to accelerate the latest advances in drug research and therapy. EarlySign’s AlgoMarkers and predictive solutions can help clients select enriched subpopulations and more accurately identify and prioritize patients for multiple conditions for interventions to halt or prevent the serious complications from the onset of disease or optimize clinical trials design and recruitment. The company’s purpose-built development environment enables fast, accurate, and explainable models supported by peer-reviewed research published by internationally recognized health organizations and hospitals.
